The Insect Peptide CopA3 Increases Colonic Epithelial Cell Proliferation and Mucosal Barrier Function to Prevent Inflammatory Responses in the Gut

J Biol Chem. 2016 Feb 12;291(7):3209-23. doi: 10.1074/jbc.M115.682856. Epub 2015 Dec 11.

Abstract

The epithelial cells of the gut form a physical barrier against the luminal contents. The collapse of this barrier causes inflammation, and its therapeutic restoration can protect the gut against inflammation. EGF enhances mucosal barrier function and increases colonocyte proliferation, thereby ameliorating inflammatory responses in the gut. Based on our previous finding that the insect peptide CopA3 promotes neuronal growth, we herein tested whether CopA3 could increase the cell proliferation of colonocytes, enhance mucosal barrier function, and ameliorate gut inflammation. Our results revealed that CopA3 significantly increased epithelial cell proliferation in mouse colonic crypts and also enhanced colonic epithelial barrier function. Moreover, CopA3 treatment ameliorated Clostridium difficile toxin As-induced inflammation responses in the mouse small intestine (acute enteritis) and completely blocked inflammatory responses and subsequent lethality in the dextran sulfate sodium-induced mouse model of chronic colitis. The marked CopA3-induced increase of colonocyte proliferation was found to require rapid protein degradation of p21(Cip1/Waf1), and an in vitro ubiquitination assay revealed that CopA3 directly facilitated ubiquitin ligase activity against p21(Cip1/Waf1). Taken together, our findings indicate that the insect peptide CopA3 prevents gut inflammation by increasing epithelial cell proliferation and mucosal barrier function.

Keywords: bacterial toxin; cell cycle; cell proliferation; epidermal growth factor (EGF); epithelial cell; inflammation; peptides; proteasome; protein degradation; ubiquitylation (ubiquitination).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Outbred Strains
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antimicrobial Cationic Peptides / pharmacology
  • Antimicrobial Cationic Peptides / therapeutic use*
  • Cell Proliferation / drug effects
  • Coleoptera / metabolism*
  • Colitis / immunology
  • Colitis / metabolism
  • Colitis / pathology
  • Colitis / prevention & control*
  • Colon / drug effects
  • Colon / immunology
  • Colon / metabolism
  • Colon / pathology
  • Cyclin-Dependent Kinase Inhibitor p21 / antagonists & inhibitors
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Enteritis / immunology
  • Enteritis / metabolism
  • Enteritis / pathology
  • Enteritis / prevention & control*
  • Gastrointestinal Agents / pharmacology
  • Gastrointestinal Agents / therapeutic use*
  • HT29 Cells
  • Humans
  • Insect Proteins / pharmacology
  • Insect Proteins / therapeutic use*
  • Intestinal Mucosa / drug effects*
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / pathology
  • Intestine, Small / drug effects
  • Intestine, Small / immunology
  • Intestine, Small / metabolism
  • Intestine, Small / pathology
  • Male
  • Mice, Inbred C57BL
  • Permeability / drug effects
  • RNA Interference
  • Tissue Culture Techniques
  • Ubiquitin-Protein Ligases / chemistry
  • Ubiquitin-Protein Ligases / genetics
  • Ubiquitin-Protein Ligases / metabolism
  • Ubiquitination / drug effects

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antimicrobial Cationic Peptides
  • CopA3 peptide, Copris tripartitus
  • Cyclin-Dependent Kinase Inhibitor p21
  • Gastrointestinal Agents
  • Insect Proteins
  • Ubiquitin-Protein Ligases